RYTM icon

Rhythm Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 70.4%
Negative

Neutral
GlobeNewsWire
4 days ago
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Neutral
GlobeNewsWire
5 days ago
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed  American Journal of Medical Genetics.
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
Neutral
GlobeNewsWire
7 days ago
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at two upcoming conferences.
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Neutral
Seeking Alpha
19 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral
GlobeNewsWire
21 days ago
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
Positive
Benzinga
27 days ago
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Neutral
GlobeNewsWire
27 days ago
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m.
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Neutral
Seeking Alpha
28 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Negative
Zacks Investment Research
28 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.81 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
28 days ago
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First quarter 2026 net product revenue from global sales of IMCIVREE of $60.1 million -- -- IMCIVREE granted Marketing Authorization by European Commission for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity -- -- Japanese regulatory review of New Drug Application for setmelanotide to treat acquired hypothalamic obesity underway -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2026.
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update